Multitargeted therapy: Can promiscuity be praised in an era of political correctness?

Critical Reviews in Oncology/Hematology

Volumn 59, Issue 2, 2006, Pages 150-158

  Jimeno, Antonio ^a   Hidalgo, Manuel ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Dual targeting; EGFR; MAPK; Promiscuous agents; Targeted therapies

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CANERTINIB; CETUXIMAB; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; MATUZUMAB; MITOGEN ACTIVATED PROTEIN KINASE; SNU 308; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR;

ACNE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BILE DUCT CARCINOMA; BREAST CANCER; CANCER CELL CULTURE; CANCER GENETICS; CANCER RESEARCH; CARCINOGENESIS; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TARGETING; DRUG TREATMENT FAILURE; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION PROFILING; HUMAN; IN VITRO STUDY; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; PANCREAS CARCINOMA; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; VASCULITIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIFFERENTIATION; CELL SURVIVAL; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 33746232407     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.01.005     Document Type: Review

References (57)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., and Thun M.J. Cancer statistics. CA Cancer J Clin 53 1 (2003) 5-26
2. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 11 (2001) 783-792
3. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 2 (2005) 123-132
4. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 4 (2004) 337-345
5. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 7 (2002) 472-480
6. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 5 (2003) 427-434
7. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 23 (2004) 2335-2342
8. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
9. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 Suppl. 4 (2001) S3-S8
10. Chen Z., Ke L.D., Yuan X.H., and Adler-Storthz K. Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells. Anticancer Res 20 2A (2000) 899-902
11. Akimoto T., Hunter N.R., Buchmiller L., Mason K., Ang K.K., and Milas L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5 10 (1999) 2884-2890
12. McClelland R.A., Barrow D., Madden T.A., et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142 7 (2001) 2776-2788
13. Grunwald V., and Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95 12 (2003) 851-867
14. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 16 (2003) 2149-2158
15. Cohen E.E., Rosen F., Stadler W.M., et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21 10 (2003) 1980-1987
16. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21 12 (2003) 2237-2246
17. Druker B.J., and David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies. J Clin Oncol 21 23 Suppl. (2003) 239s-245s
18. Kantarjian H., Sawyers C., Hochhaus A., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346 9 (2002) 645-652
19. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 23 (2003) 4342-4349
20. Reddy G.K. The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial. Clin Colorectal Cancer 4 5 (2005) 300-301
21. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 21 (2004) 2129-2139
22. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 5676 (2004) 1497-1500
23. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 36 (2004) 13306-13311
24. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 2 (2005) 133-144
25. Worthylake R., Opresko L.K., and Wiley H.S. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 274 13 (1999) 8865-8874
26. Christensen J.G., Schreck R.E., Chan E., et al. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res 7 12 (2001) 4230-4238
27. Viloria-Petit A., Crombet T., Jothy S., et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61 13 (2001) 5090-5101
28. Viloria-Petit A.M., and Kerbel R.S. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys 58 3 (2004) 914-926
29. Ng S.S., Tsao M.S., Nicklee T., and Hedley D.W. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 1 10 (2002) 777-783
30. Li B., Chang C.M., Yuan M., McKenna W.G., and Shu H.K. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 63 21 (2003) 7443-7450
31. Tabernero J., Rojo F., Jimenez E., et al. A phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Proc Am Soc Clin Oncol 22 (2003) 192 [Abstract 770]
32. Bianco R., Shin I., Ritter C.A., et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22 18 (2003) 2812-2822
33. Chakravarti A., Loeffler J.S., and Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62 1 (2002) 200-207
34. Pollack V.A., Savage D.M., Baker D.A., et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 291 2 (1999) 739-748
35. Moyer J.D., Barbacci E.G., Iwata K.K., et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57 21 (1997) 4838-4848
36. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., and Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1 11 (1995) 1311-1318
37. Fan Z., Lu Y., Wu X., and Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269 44 (1994) 27595-27602
38. Wu X., Rubin M., Fan Z., et al. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 12 7 (1996) 1397-1403
39. Ciardiello F., Bianco R., Damiano V., et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6 9 (2000) 3739-3747
40. Allen L.F., Sebolt-Leopold J., and Meyer M.B. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 30 5 Suppl. 16 (2003) 105-116
41. Jimeno A., Rubio-Viqueira B., Amador M.L., et al. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 65 8 (2005) 3003-3010
42. Huang S., Armstrong E.A., Benavente S., Chinnaiyan P., and Harari P.M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 64 15 (2004) 5355-5362
43. Matar P., Rojo F., Cassia R., et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 10 19 (2004) 6487-6501
44. Tortora G., Caputo R., Damiano V., et al. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res 9 4 (2003) 1566-1572
45. Burris H., Taylor C., Jones S., et al. A phase I study of GW572016 in patients with solid tumors. Proc Am Soc Clin Oncol 22 (2003) 248 [Abstract 994]
46. Blackwell K., Kaplan E., Franco S., et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 23 (2004) [Abstract 3006]:196
47. Belanger M., Jones C., Germond C., and Berger M. A phase II, open-label, multicenter study of GW572016 in patients with metastatic colorectal cancer refractory to 5-FU5-FU in combination with irinotecan and/or oxaliplatin. Proc Am Soc Clin Oncol 22 (2003) 244 [Abstract 978]
48. Erlichman C., Boerner S.A., Hallgren C.G., et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 61 2 (2001) 739-748
49. Calvo E., Tolcher A.W., Hammond L.A., et al. Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study. Clin Cancer Res 10 21 (2004) 7112-7120
50. Campos S., Hamid O., Seiden M.V., et al. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol 23 24 (2005) 5597-5604
51. Ciardiello F., Bianco R., Caputo R., et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10 2 (2004) 784-793
52. Tuccillo C., Romano M., Troiani T., et al. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. Clin Cancer Res 11 3 (2005) 1268-1276
53. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 19 (2004) 7099-7109
54. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 1 (2003) 327-337
55. Roberts Jr. T.G., Lynch Jr. T.J., and Chabner B.A. The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. J Clin Oncol 21 19 (2003) 3683-3695
56. Mencher S.K., and Wang L.G. Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin Pharmacol 5 1 (2005) 3
57. Roth B.L., Sheffler D.J., and Kroeze W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3 4 (2004) 353-359